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Abstract 
Introduction: The cost of in vivo and in vitro screening of ADME properties of compounds 
has motivated efforts to develop a range of in silico models. At the heart of the development 
of any computational model are the data; high quality data are essential for developing robust 
and accurate models. The characteristics of a dataset, such as its availability, size, format and 
type of chemical identifiers used, influence the modelability of the data. 
Areas covered: This review explores the usefulness of publicly available ADME datasets for 
researchers to use in the development of predictive models. More than 140 ADME datasets 
were collated from publicly available resources and the modelability of 31selected datasets 
were assessed using specific criteria derived in this study. 
Expert opinion: Publicly available datasets differ significantly in information content and 
presentation. From a modelling perspective, datasets should be of adequate size, available in 
a user-friendly format with all chemical structures associated with one or more chemical 
identifiers suitable for automated processing (e.g. CAS number, SMILES string or 
InChIKey). Recommendations for assessing dataset suitability for modelling and publishing 
data in an appropriate format are discussed. 
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1. Introduction 
The ability of a compound to elicit any biological effect (be that a desirable therapeutic effect 
or an undesirable toxic effect) depends on two factors: the intrinsic activity of the compound 
and its potential to reach the site of action in sufficient concentration for the requisite time 
period. The likelihood of the compound reaching any given site depends on both the external 
and internal exposure [1]. External exposure relates to the possibility of the compound 
reaching an organism, i.e. the concentration present in the environment to which the organism 
is exposed. Internal exposure relates to the uptake and distribution of the compound to sites 
of action within an organism, its metabolism and ultimate elimination from the body. These 
properties of a compound, termed absorption, distribution, metabolism and excretion 
(ADME), will determine the concentration-time profile of the compound at a given site of 
interest or in the body as a whole. These factors are therefore important in determining the in 
vivo response to a potential therapeutic agent or a toxicant as they may have a significant 
modulating effect on overall activity. Knowledge of ADME properties is critical in the 
development of new drugs and in assessing the risk posed by compounds such as industrial 
chemicals, food additives, pesticides and environmental pollutants, to which an organism 
may be exposed to [2]. For example, negligible absorption via a given route may provide a 
scientific justification for waiving certain toxicological studies. ADME data can also assist in 
the interpretation of animal studies, particularly with respect to identifying inter-species 
differences or similarities [3]. Moreover, information on ADME properties is crucial for the 
development of appropriate toxicity testing strategies, including the selection of appropriate 
species and doses for toxicity testing, and for risk assessment enabling comparison of internal 
dose in experimental animals and humans [4].  
Knowledge of ADME properties of category members is also recognised as being useful in 
substantiating read-across approaches for data gap filling [5]. ADME data can provide insight 
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as to which tissues/organs are exposed, as well as the kinetics of this exposure. Within a well-
defined category, or for structural analogues, that are assumed to be acting by the same 
mechanism of action, knowledge of toxicokinetics will assist in justifying a read-across 
prediction.  
ADME data can be generated using in vivo, in vitro and/or in silico methodologies. However, 
in vivo and in vitro evaluation methods are costly and time consuming; with in vivo methods 
having the additional, undesirable requirement for animal use. These methods are not suitable 
for testing large numbers of chemicals. Therefore, over the past three decades interest has 
grown in in silico methodologies and consequently a large number of models have been 
developed to evaluate ADME properties, particularly as part of the drug discovery process. 
The purpose of the present paper is not to review the models themselves as several excellent 
reviews regarding the development of such models have already been published [2, 6-11]. 
The aim here was to evaluate the nature of the publicly available datasets for ADME 
properties, such as to inform potential, future model builders as to the suitability for 
modelling of each dataset. The advantage of developing in silico models is that, being high-
throughput and low cost, they can be used to (virtually) screen thousands of compounds, in a 
short time to help prioritise compounds for further testing or development [11].  
To develop a reliable in silico model, ideally a significant number of high quality 
experimental data are needed [9]. Whilst screening for ADME properties may be routine in 
drug development, this does not result in a commensurate high availability of data in the 
public domain that may be used by modellers - for reasons of confidentiality [12]. Of those 
data that are available, they may be stored within a database and/or a dataset. The former is 
defined here as an organised collection of data that may be logically searched or retrieved, 
under the control of database management software; the latter refers to any set of data, 
usually presented in table format, that may be readily processed computationally (the dataset 
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may be extracted from a database, or available in a standalone format). Many businesses will 
possess their own in-house ADME databases; however, publicly available data that can be 
obtained rapidly and with little or no cost are preferable, particularly for academia. There are 
a number of publicly available databases, such as PubChem [13], DrugBank [14], ChEMBL 
[15] and ACToR [16], where a reasonable number of ADME–related data can be sourced. 
However, such data for ADME endpoints very often need to be extracted using appropriate 
data retrieval techniques [17] and then collated and organised in a tabular format. A relatively 
large number of ADME data are available in the ADME SARfari database [18, 19]. 
However, data for all ADME endpoints are collated together in one file, which necessitates 
selective extraction of the data of interest. An additional difficulty is that the chemical 
identifiers are stored in a separate file, therefore the chemical structures from one file have to 
be assigned to datapoints from another file. ADME-related data, compiled in a single place to 
create a tabular data matrix, are more attractive and useful for modellers. Ready-made ADME 
datasets are usually obtained from peer-reviewed literature, reports or from ADME online 
databases, such as the PharmacoKinetics Knowledge Base (PKKB) [20].  
Whilst many datasets are available, there is no standard template, generally accepted by 
scientific journals, for publishing data i.e. no formally adopted standards on how chemical 
structures should be represented, which biological information should be available and the 
level of experimental detail that should be recorded and in which format. There are examples 
of published guidelines, such as the reporting guidelines for bioactive entities— the 
Minimum Information About a Bioactive Entity (MIABE) — which is a formal list of the 
items of information about a molecule, its properties, production, physicochemical 
characteristics, biological activities (obtained using in vitro cell-free assays, cellular assays, 
whole-organism studies or pharmacokinetic studies) that are recommended to be published 
by the data provider [21]. These guidelines were developed by representatives of 
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pharmaceutical companies, data resource providers and academic groups and are proposed to 
be used during manuscript preparation to make all data on bioactive molecules readily 
available in a single common format, with a full and consistent data description. Fourches et 
al. proposed a set of procedures for chemical data curation that should be followed at the 
onset of any molecular modelling investigation [22]. Additionally, for certain endpoints 
guidelines or checklists for recording experimental information have been promoted 
previously [23, 24]; recording and analysis of metadata and associated data governance 
considerations (in the context of different toxicity endpoints) has been reviewed by Fu et al 
[25]. However, none of these guidelines or strategies have been implemented in a standard 
procedure for publishing data in publicly available domains. Therefore, publicly available 
datasets differ in terms of information content and presentation as well as in overall intrinsic 
data quality. Modellers using readily-available datasets from public resources rely largely on 
the data providers for curation, accuracy and consideration of quality. Whilst any dataset 
compilation should be quality checked for the correctness of the chemical and biological 
information and overall intrinsic quality of the data, these processes are not obligatory and 
are seldom, if ever, recorded.  
Quality assurance of published datasets should consist of three stages: 
(i) Chemical structure characterisation 
It is crucial to ensure that the chemical structures are reported correctly and characterised by 
consistent, unambiguous chemical identifiers. Incorrect structures [26], inconsistency 
between the chemical identifiers [27] and/or their ambiguity (i.e. whether an identifier 
matches more than one chemical structure) [28] pose a significant problem for the 
development of predictive models. Aside from the correctness of chemical identifiers, the 
curation of chemical structures influences the predictive performance of models significantly 
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[22]. The data curation process may include: the removal of mixtures, inorganics and 
organometallics; structure conversion; cleaning / removal of salts; normalisation of specific 
chemotypes; treatment of tautomeric forms; and identification / removal of duplicates. [22]. 
Despite automation, structure curation may still require significant manual inspection both to 
determine which changes are needed in the analysis stage and post processing to verify that 
the changes have the desired effect. Only well curated chemical data have the potential to 
generate models with reasonable robustness and reliability [22, 29]. 
(ii) Biological information assessment 
Biological details, such as the nature of the experiment, whether it is in vivo or in vitro, 
species, sex, strain of animals /organisms and experimental conditions (duration, dose, 
vehicle etc.) should be carefully assessed for consistency and correctly reported. For 
example, in terms of developing predictive models, the vehicle (or co-administered 
substances) used for a given experiment may have a significant effect on the outcome. 
Modellers need to determine in which cases results using different vehicles can be combined 
and when they require the development of alternate models. There are a number of studies, 
both experimental and in silico that have investigated the influence of the vehicle on 
biological activity. For example, Jowsey et al. showed that for certain vehicles the variation 
in the measured skin-sensitisation potential of compounds (determined using the local lymph 
node assay (LLNA)) was no greater than the expected experimental variability. However, for 
other vehicles the potency values recorded for the same compound in different vehicles 
varied by a factor of 10 [30]. Mistry et al. produced random forest and decision tree models 
to investigate the influence of different drug-vehicle combinations on drug toxicity, enabling 
vehicle selection to be optimised to reduce toxic effects [31]. Ghafourian et al. developed 
quantitative structure activity relationships (QSARs) models to predict skin permeability 
coefficients of compounds dissolved in different vehicles [32]. Moreover, when data are 
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combined from more than one species, it can have a great effect on the results. Significant 
inter-species differences in response will affect the accuracy of predictions when scaling 
between one species and another [24]. Also intra-species variations, such as differences in 
age, gender can influence the in vivo outcomes and subsequently the correctness of 
predictions [24]. Such issues of variability can only be determined if the relevant biological 
information is recorded.  
When data are collated from different sources, multiple values of biological activity for the 
same chemical may be found even within one dataset. Where the values are comparable, it is 
relatively easy to define a representative value using standard statistical procedures, such as 
median [33], geometric mean [34, 35] or arithmetic mean [36]. When values for one chemical 
differ from others by orders of magnitude or are outside of the range of ±50% of the median, 
such data can be considered as outliers and may be omitted [37]. Another option is to remove 
any obviously unreliable data points and then select the lowest value for the EC50 from the 
remaining data [38]. This is a conservative approach where the lowest dose associated with a 
given toxic response is assumed is used. It is worth mentioning, that the presence of multiple, 
comparable values for the same chemical can increase confidence in the data and this may be 
expressed as a confidence score (CS), and the use of such data will consequently improves 
the robustness of the model [39]. 
In cases where conflicting biological results have been identified, more detailed investigation 
into the studies to identify potential sources of variation is required [40]. On this stage, the 
importance of understanding biological data is vital. Where an obvious reason for 
discrepancy in biological activity cannot be found then a weight of evidence approach may be 
used i.e. confirmation is sought from additional sources. If the conflict between data values 
cannot be resolved then the data should be excluded from modelling.  
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(iii) Assessment of intrinsic data quality 
Assuring data quality, although time consuming, is of key importance as it directly influences 
the predictive performance of models. There is a universal agreement that models are only as 
good as the data on which they are based [41]. The importance of data quality assessment and 
the need for an appropriate scheme and/or tool for such assessments is widely recognised and 
has been discussed in detail elsewhere [40, 42-45]. Ideally, the data should be reported in a 
manner which is conducive to quality assessment [46]. This requirement is particularly 
pertinent to the drug discovery process, here the emphasis has shifted from the development 
of predictive models, to the need for techniques to manage, curate, and integrate large 
amounts of potentially useful data [46].  
Such quality controlled datasets are at the heart of developing reliable in silico models. There 
are various methods for generating models to predict biological endpoints, such as statistical 
techniques developing e.g. QSARs models or expert system approaches such as structural 
alerts. These methodologies have been discussed in depth elsewhere [47] and they are beyond 
the scope of this review as here the focus is on the data itself rather than the models 
generated. When selecting an in silico model to use it is crucial to understand the strengths 
and limitations of each model [48]. The predictive strength of an in silico ADME model 
influences at which stage of the drug development process the model can be most gainfully 
employed [48].  
For modellers, there are additional characteristics of a dataset that significantly influence the 
ability to model the data therein (referred to in this paper as “modelability”) [49]. In general, 
the most favourable datasets for modelling consist of a large number of compounds 
characterised by machine-readable identifiers (enabling automated processing) and recorded 
in a user-friendly format. These aspects of datasets that influence their modelability will be 
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discussed and evaluated in this review. Therefore, the aims of this work were: to define the 
characteristics of datasets that are important for modellers to consider when selecting the 
most appropriate dataset for model development (i.e. to determine characteristics influencing 
modelability); to identify publicly available resources for ADME properties; to assess the 
usefulness of these ADME datasets for modelling purposes; and, finally, to make 
recommendations to help modellers select the most appropriate dataset(s).  
2. Characteristics of datasets that influence their modelability 
In general, datasets appropriate for modelling for any endpoint/biological activity combine 
two types of information: chemical and biological. The manner in which such data are 
presented to the user constitutes the characteristics of the dataset and determine their 
modelability. The relationships between these factors are shown in Figure 1 and are discussed 
individually below. 
The information needs to be presented in a well organised and transparent manner which is 
easy to understand and use. Specific characteristics that influence suitability for modelling 
include: availability, size, format and types of chemical identifiers used (which determines 
how quickly and easily the data can be processed computationally) and accuracy. Whilst 
intrinsic data quality is essential for building reliable models, data quality assessment has 
been extensively reviewed elsewhere, as indicated above. Hence this review relates to the 
modelability of data, in terms of its presentation to the user, rather than considering intrinsic 
data quality. 
2.1 Availability 
With regard to the availability of data, there are public, commercial or in-house databases. 
Commercial databases may be richer in data and more diverse than publicly available 
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sources. In-house databases may be more diverse or may be specifically focused on the 
chemical spaces of interest to the company, however, they have the significant advantage that 
the data are often more consistent with less experimental variability than other sources [50]. 
Publicly available datasets may be smaller; larger datasets are generally collations from 
multiple sources and therefore have much higher experimental variability due to inter-
laboratory differences in procedures. The main advantage of public datasets is their free 
accessibility; hence they are highly desirable and extensively used by modellers.  
2.2 Size 
Another aspect important for the development of a model is the size of the dataset, which has 
a significant impact on chemical space and range of activity covered by the model. Publicly 
available datasets are often created by collation of data from various sources. This means that 
the data may be measured in different laboratories using different experimental 
procedures/conditions resulting in significant inter-laboratory differences [12]. Generic and 
endpoint-specific sources of experimental variation are discussed in Madden et al. [24]. As 
smaller datasets may be iteratively collated into larger datasets, there is a possibility of 
repetition of data, hence the number of unique compounds needs to be confirmed. Collation 
may lead to problems of perpetuating errors appearing in earlier publications or introducing 
new errors on processing. Such heterogeneous datasets cover a wider chemical space, this 
diversity renders them attractive to modellers. However, variability may reduce the maximal 
accuracy that can be obtained for the models [51, 52]. For collated datasets, it is important 
that references to the original sources of experimental results are provided allowing for 
verification of results, if necessary, and giving access to additional information for the 
chemicals tested. Conversely, homogenous datasets use data from a single study (or a small 
number of studies) carried out under the same experimental protocol, in the same laboratory, 
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possibly by the same operator. Such datasets are smaller, have reduced experimental 
variability and may cover a narrower activity range, resulting in models with potentially 
greater accuracy but with a reduced applicability domain.  
2.3 Format 
Data can be recorded in many different file formats, examples include: Excel, comma-
separated values (CSV), Text, Word, portable document format (pdf), structure-data file 
(sdf), hypertext markup language (html) and a number of other formats. It is important for 
modellers to have data in a user–friendly format, which is easy to handle and allows for ready 
data analysis and/or manipulation. An Excel file, whilst limited in some aspects (e.g. linkage 
to chemistry), is an appropriate format as it allows for a variety of manipulations, as well as 
easily importing or exporting data (both individual values and large collations). Data 
recorded in CSV and Text formats are also suitable for modellers, as these data can be easily 
imported to Excel files. The sdf format offers clear visualisation of chemical structures [53], 
however, not all software recognise this format and it is not possible to readily manipulate 
data in this format. Word and pdf formats are less attractive to modellers, as they cannot be 
processed by computational chemistry or statistical software. Some datasets have been 
published graphically, e.g. in graphic interchange format (gif) however, again this is not 
suitable for modelling as data must be manually converted into a more suitable format. 
2.4 Types of chemical identifiers 
Finally, the type of chemical identifiers used has a significant impact on model development. 
There are a number of potential identifiers and systems by which a chemical structure can be 
represented [40]: 
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• Nomenclature: International Union of Pure and Applied Chemistry (IUPAC) names, 
common names, inventory or database names 
• Unique Identifiers: Chemical Abstracts Service (CAS) registry numbers, inventory or 
database numbers (e.g. ChemSpider ID number; European INventory of Existing Commercial 
chemical Substances (EINECS) number) 
• Line notation methods: Simplified Molecular Input Line Entry System (SMILES) 
strings [54], IUPAC International Chemical Identifier (InChI) code [55], empirical formula 
• Pictorial representations in 2 or 3 dimensions. 
• Representation of 3-dimensional structures (e.g. mol, sdf files) 
To ensure the accuracy of chemical identity, at least two, and ideally three concordant 
identifiers should be provided in the dataset. Having three concordant identifiers, such as 
chemical name, CAS registry number and structure, is a strong indication that the chemical 
identity is correct. Any lack of consistency between the chemical identifiers for a compound 
would require further investigation or exclusion of the compound from the dataset.  
From the modeller’s perspective, it is preferential to utilise identifiers encoding the chemical 
structure in a form which is easy to interpret and can be easily input into, and recognised by, 
a range of different software. SMILES strings fulfil these criteria; therefore, datasets with 
chemicals identified by SMILES annotations are valuable for developers of predictive 
models. However, SMILES strings also have their shortcomings; they focus on molecules 
with bonds that fit the 2-electron valence model, have a limited array of stereochemistry 
types and have no standard for handling aromaticity [56]. Also the issue of multiple 
tautomers of the same molecule cannot be handled adequately by SMILES notation as it 
stretches the conceptual limit of a unique chemical identifier [57, 58]. Moreover, there is no 
standard means to generate canonical SMILES, as toolkits create canonical SMILES 
differently [56]. There have been attempts to overcome this limitation, such as the 
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introduction of universal SMILES, based on the InChI canonicalisation algorithm [56], but 
this remains a restriction to their universal applicability. 
These four characteristics of datasets, (availability, size, format and types of identifier used), 
were considered to be key criteria for assessing their suitability for modelling and were 
adopted as the evaluation criteria for the datasets investigated within this study. 
3. The identification of publicly available ADME datasets 
In general, ADME properties can be classified into one of two categories: physiological and 
physico-chemical [50]. A number of physiological ADME properties have been identified in 
this investigation covering the four fundamental processes of absorption, distribution, 
metabolism and excretion. Physiological ADME properties can be further sub-divided into in 
vitro ADME properties (such as uptake across the human epithelial colorectal 
adenocarcinoma (Caco-2) cell line or the Madin-Darby Canine Kidney (MDCK) cell line) 
and in vivo pharmacokinetic properties (such as oral bioavailability, human intestinal 
absorption (HIA), plasma protein binding (PPB) and urinary excretion). Table 1 summarises, 
with brief definitions, the physiological ADME properties investigated in this study. Table 1 
is not exhaustive, but covers a wide range of the most significant pharmacokinetic / 
toxicokinetic properties for which models are required. For the purposes of this investigation 
some related properties have been grouped together (refer to third column in Table 1) as the 
individual properties are representative of related (or the same) endpoints. For example, 
datasets for percentage absorption (% abs) – here referring to absorption across the gastro-
intestinal tract have been grouped together with datasets that refer specifically to percentage 
human intestinal absorption (%HIA). Similarly, datasets for fraction bound/fraction unbound 
in plasma were grouped with percentage plasma protein binding (%PPB) as the latter datasets 
were more populous. Physico-chemical properties (governed by the Laws of Physical 
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Chemistry) include aqueous solubility, the logarithm of octanol–water partition coefficient 
(log P), logarithm of octanol–water distribution coefficient (log D) and acid dissociation 
constant pKa [50]. These are data rich properties that have been extensively reviewed 
elsewhere, [59-63], thus they were excluded from this analysis. 
Data for the ADME properties identified in Table 1 were retrieved by a thorough literature 
search and review of online resources. Only freely available datasets were considered as they 
are most useful for modelling. Two online ADME databases: PKKB [18] and PK/DB [64] 
were used as the starting point for this search. These databases provide compiled datasets for 
several ADME endpoints, including: Caco2 permeability, blood-brain permeability, PgP 
inhibition, oral absorption and oral bioavailability. In addition to the online databases, two 
extensive reviews were used as a source of available ADME datasets [1, 8]. By preference, 
the most recent collations of the experimental data for the ADME properties identified were 
usually considered as they were the most comprehensive and up to date. 
In total, 141 ADME datasets were identified using the above procedure, these covered the 
majority of the individual (or grouped) ADME properties given in Table 1. Information for 
each of these endpoints were stored on separate Excel spreadsheets that included the 
following fields: dataset identity number, key reference source, availability/licencing 
requirements, format of data (e.g. sdf, pdf etc.), number of compounds in dataset, chemical 
identifiers used (e.g. names, SMILES, CAS), nature of biological data (i.e. in vivo or in vitro 
assay; species used), additional endpoint data available from the same references (some 
references included large collations of multiple endpoints and / or physico-chemical property 
data), diversity of chemicals (i.e. whether all chemicals were drugs, drug-like or 
representative of many areas of chemical space), whether the data were a collation or 
obtained from a single source, availability of supporting documentation (i.e. availability of 
original references), additional comments (where appropriate) and hyperlinks to the original 
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publication / website from where the dataset can be obtained (subject to appropriate user / 
institutional journal access rights). This Excel file is available as supporting information.  
Some ADME endpoints, such as: absorption, bioavailability and blood-brain barrier (BBB) 
partitioning are rich in data, for others, there is a scarcity of data. For three endpoints (uptake 
by the respiratory tract, fraction bound/unbound in tissues and kinetic data) no suitable 
datasets were obtained. However, for uptake by the respiratory tract studies on single 
chemicals have been identified and for kinetic data (e.g. Cmax, Tmax) values for a small 
number of individual compounds are available in DrugBank [14]. From inspection of the 
datasets different recording formats were apparent. Approximately 70 of the datasets were 
published as pdf files and only 33 datasets were in Excel format (less common formats used 
were Word files, sdf files, CSV etc.). The datasets ranged in size from fewer than ten 
compounds to several thousand compounds. The majority of datasets were collations from 
diverse sources using different experimental procedures, usually, the source of the primary 
experimental data was given (level of experimental detail was variable). Only ten datasets 
provided data from a single source where all chemicals were tested according to the same 
experimental protocol. The chemicals were characterised using up to three identifiers, 
including: name, CAS number, SMILES string and/or pictorial representation; however, in 
most cases, the compounds had only one identifier. Since the majority of ADME data came 
from drug discovery, they were usually identified by common/marketing names, which may 
present problems for obtaining alternative identifiers that encode structure, such as SMILES 
strings or InChI keys. Although not an exhaustive list of available datasets, not least as the 
number is continually expanding, this was considered a good selection to carry forward to the 
next step of the process -assessment of suitability for modelling.  
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4. The assessment of the selected datasets in terms of their usefulness for modelling 
purposes 
From the modeller’s perspective, the “ideal” dataset should be publicly available (in a user-
friendly file format such as Excel), reasonably large with diverse chemicals and described by 
an adequate number of concordant identifiers. A selection of the ADME datasets identified 
were assessed for their suitability for modelling using the four characteristics discussed above 
(i.e. availability, size, format and type of chemical identifiers used). In general, the largest 
data set for each ADME endpoint was investigated. In some cases, more than one dataset was 
evaluated e.g. where datasets were of a similar size, or where datasets covered different 
biological effects / activities (such as different sub-types of transporters). In total, 31 datasets 
were selected for assessment. Table 2 shows the datasets chosen for assessment together with 
information on their original format and available chemical identifiers.  
4.1 Availability 
The free availability of data was the essential criterion when considering ADME datasets in 
this analysis. Other sources of ADME data, such as commercial databases, were not 
considered. Thus, all ADME datasets identified herein are publicly available either from 
publications (or supporting information / on request from authors), book chapters or online 
databases. Certain online databases require registration with the database administrator prior 
to receiving a free licence or password, journal access is subject to usual user access 
restrictions. 
4.2 Size 
The size of the dataset (i.e. the number of unique compounds) was chosen as the next 
selection criterion for the assessment of their usefulness for in silico modelling. The optimal 
size of a dataset for modelling purposes is arbitrary; it depends on several factors, such as the 
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(statistical) method used to generate the model [29]. A larger dataset often means greater 
diversity, and hence coverage, of chemical space which, in turn, provides a wider 
applicability domain for any model developed therefrom. 
Moreover, models built upon large training datasets are likely to be more robust than those 
developed using smaller training sets. In predicting toxicity, ensuring consistency in the 
putative mechanism of action of compounds in the training set (which may lead to reduction 
in training set size) is an important consideration, this is, however, less of an issue in 
predicting ADME endpoints [65, 66]. 
Analysis of the selected datasets shows that they range in size from fewer than ten 
compounds to thousands of chemicals. The smallest datasets were those for compounds 
crossing the blood:testis barrier with only 6, 7 and 10 chemicals in the three available 
datasets, respectively [67-69]. The largest datasets, comprising several thousand compounds, 
were obtained for: interactions with transporters (e.g. 3,763 chemicals interacting with 12 
membrane transport proteins [70]), BBB partitioning (2,053 chemicals with binary data [71]), 
or Caco2 permeability (1,301 compounds with the maximum and minimum values of 
permeability given [72]). In some cases, it may be appropriate to sub-divide the dataset into 
smaller groups. For example, sub-dividing acidic and basic compounds, or those that interact 
with specific transporters, however, such decisions remain within the remit of the modeller 
and the purpose for which they are using the dataset  
4.3 Format 
The datasets selected for analysis were published in a number of different formats (see Table 
2): Excel (15 datasets), .pdf (10 datasets), .sdf (2 datasets), text (1 dataset), Word (2 datasets) 
and .gif (1 dataset). If the data are to be used for modelling, they should be recorded in a 
format which is easily accessible and allows for quick and simple data extraction and 
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analysis. Although proprietary, the Excel format is user-friendly for reporting and storing 
data and is widely available. Excel spreadsheets allow for transparent and logical storage of 
multiple data points which can be readily manipulated; a single datum point or, group of data, 
can be extracted from Excel and processed using a variety of other software. Therefore, the 
existing 15 datasets published in Excel format were assessed as having a user-friendly data 
format. It should be appreciated that whilst good for storing data, Excel is not a database 
format and is not able to link to chemistry-based searches etc.  
The usability of other data formats was assessed by attempting to convert the data into a 
format that could be readily incorporated into Excel. Conversion from Text format (as 
applied to a BBB dataset [71]), using appropriate delimiters in Excel, was the most 
straightforward conversion. Bioavailability and transporter datasets, reported as Sdf files [73, 
74], could be readily converted to CSV formats and subsequently read into Excel, therefore 
were also considered suitable formats. Conversion from Word files (as performed for blood : 
testis and milk : plasma datasets [67, 75]) is easily achieved for some formats (e.g. if data are 
stored in a standard table). However, where there is additional formatting within the table 
(such as merged cells) then manual inspection of the transferred data is necessary – hence this 
format is only suitable for smaller datasets. Conversion from pdf to Excel (using Adobe 
Acrobat Pro software [76] resulted in several problems such as: specific characters being 
incorrectly converted, columns being inappropriately merged, data points appearing in 
incorrect cells etc. This means that careful, time-consuming manual curation is essential, 
rendering pdf a less suitable format. The dataset for skin absorption (Jmax) values was 
published as picture format, .gif file [77]. As all data then requires manual extraction this was 
considered the least useful format for the datasets considered here. 
4.4 Chemical identifiers 
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Unambiguous, chemical identifiers that can be used to relate a chemical structure to a given 
property are essential for modelling. There are well recognised problems with using chemical 
names and CAS numbers (e.g. lack of consistency, conversion errors on entering into Excel 
etc. [70, 78,]), although they should add certainty to the identity of chemicals. Many 
structures have historically been stored as SMILES strings, although these can have different 
formats and interpretations and isomers can also present problems. The InChI format may be 
a better solution, but even that does not assist in the capture of 3-D information - that would 
require, for example, an .sdf file. The InChI uses a layered format to represent all the 
available structural information (formula, connectivity, isotopes, stereochemistry and 
tautomers) relevant to compound identity [79].  
The selected datasets differed in the number of identifiers used: for only three datasets 
chemicals were characterised by three identifiers: name, CAS number and SMILES strings. 
Five datasets were characterised by name and CAS number; nine datasets by name and 
SMILES strings; 14 datasets provided the name only. Machine-readable identifiers (such as 
SMILES strings) are important to modellers to enable automated processing of the data in a 
range of software. Translating other identifiers into SMILES can be achieved by automated 
processing, however there are caveats to this. ChemSpider [80] can be used to convert from 
names to InChIKeys, from which an MDL molfile can be downloaded. The OpenBabel [81] 
node within KNIME [82] can then convert MDL to SMILES. Problems arise where non-
systematic (e.g. generic or brand names) or incorrect names are used and it should be noted 
that some structures may not be available within public data resources or may be incorrectly 
recorded. Manually obtaining and/or curating identifiers may therefore be necessary to ensure 
accuracy. Datasets comprising two or more concordant identifiers, including at least one in a 
machine-readable format are therefore considered most suitable for modelling. On the other 
hand, datasets with only one identifier, most often name, are the least favoured for modellers, 
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as the translation of names into an identifier encoding structure, such as SMILES, is required. 
Additionally, the presence of only one identifier for the chemical adds uncertainty to the 
identity of the tested compound, especially if the names are incorrectly recorded or non-
standard. The summary outcome of assessment of the datasets considered, in terms of 
availability, size, format and chemical identifiers used, is given in Table 2.  
5. Conclusions  
Publicly available datasets have been sourced for 24 ADME properties. However, only a 
small number of endpoints, such as oral absorption and bioavailability are rich in 
experimental data; for many other ADME properties, there is a scarcity of data. The data are 
the bedrock of the development of computational models and are of key importance in drug 
development and / or to assess the potential for toxicity. The so-called modelability of a 
dataset is influenced by its availability, size, format and types of chemical identifier used. 
These criteria were used to assess the usefulness of the datasets obtained in this study for 
modelling purposes. Generally, the largest datasets were chosen for assessment for each 
ADME endpoint, as larger datasets are favoured by modellers, although those considered 
varied in size from fewer than 10 compounds to several thousand. With regards to format, 
approximately half were published in Excel (considered to be the most favourable format) 
with the remaining datasets being in sdf, pdf, Text, Word or Gif formats. SMILES strings 
were the preferred identifier, although these were only available for twelve of the datasets; 
SMILES strings were created for the remaining datasets.  
In summary, this study has developed criteria for assessing the usefulness of publicly 
available datasets for (Q)SAR modelling and applied these criteria to 24 ADME endpoints. 
As a result, 31 “benchmark” ADME datasets are identified for modellers to use (details are 
available within the supplementary information). 30 of these datasets are provided in Excel 
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files as supplementary information. One dataset for skin absorption (Jmax) values [77], was 
published as gif file, this was assessed as unsuitable for modelling and consequently has not 
been converted into an Excel file format here. 
6. Expert opinion 
Although, there is still a scarcity of experimental data for some ADME properties, especially 
in public resources, a large number of ready-made datasets have been published for other 
endpoints. Such datasets present great potential for generating in silico models. However, the 
datasets differ in their characteristics as there are no standard widely accepted guidelines as to 
how they should be reported. Here we undertook an assessment of usefulness of publicly 
available ADME datasets for modelling and have shown that adherence to standardised 
guidelines for format and contents would be of great assistance for modellers. 
The choice of dataset is in part determined by the type of model being developed, for 
example considering whether a global model (requiring a larger, more chemically diverse 
dataset) or a local model is more desirable. It is acknowledged that, where appropriate, 
consideration must also be given to mechanism of action, although this is generally more 
relevant to toxicity prediction than ADME prediction. Intuitively modellers may select the 
largest dataset, leaving other factors, such as format and types of chemical identifiers used, as 
second-tier criteria for selection. This study has shown data format has a significant impact 
on dataset modelability. Therefore, size and format should both be considered pragmatically 
in the first stage of dataset selection. Also important, is the correct identification of chemicals 
by ideally three concordant identifiers. Datasets with chemicals identified by name only are 
potentially the most misleading and require additional processing i.e. names require 
transcription into identifiers encoding structure. Although this process may be automated to 
some extent, manual verification or and / or retrieval of identifiers may still be necessary. 
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Misspelt, ambiguous or non-standard names can be difficult to verify and therefore such 
chemicals have to be removed from the dataset. Therefore the presence of at least one 
identifier which encodes the chemical structure and is machine-readable is preferable for 
modelling purposes. SMILES format is the most popular line notation, being easily generated 
and interpreted by both humans and software. However, there are disadvantages to SMILES 
strings, such as a limited array of stereochemistry types, lack of standardisation for 
representing the aromaticity or handling multiple tautomers. The greatest limitation of the 
SMILES format is that there is no standard means to generate a canonical representation [56]. 
Therefore, it is recommended to standardise SMILES strings using a single canonicalisation 
algorithm for the dataset of interest. Recently an alternative line notation identifier (the InChI 
string) has become more widely applied. Although the InChI does resolve some of the issues 
with SMILES it has the disadvantage of requiring software for its interpretation [99, 100].  
Aspects associated with the intrinsic accuracy of the data, such as correctness of chemical and 
biological details, are usually assessed by the developers of the datasets. Although a modeller 
may use the data without further quality assessment, use of data that has been quality assured 
in some way is preferable. To enable checking of chemical and / or biological information 
within a dataset, the availability of the reference to the original study is crucial. Therefore, the 
providers of the datasets should ensure this information is recorded, wherever practicable, 
during the collation and organisation of the data. In the case of multiple values being 
recorded for the same chemical the modeller must judge the most pragmatic approach; for 
example using a median or mean if the values are sufficiently “similar”, or rejecting as 
outliers values that are extreme or anomalous. For this reason modellers require some 
appreciation of the level of variation inherent within a given assay to enable realistic 
boundaries for results to be determined. This requires information on how the result was 
obtained, the experimental protocol used and how experimental factors can impact the test 
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result (e.g. solubility limitations for compounds studies, use of solvents, alternative routes of 
exposure, etc.) [101]. Weight of evidence approaches may assist in cases where highly 
variable or contradictory data are recorded, resulting in higher confidence being assigned to a 
particular value or identifying data that should be excluded. The modelling process itself may 
identify anomalous data points which can then be queried or rejected as necessary. The 
overall characteristics of an ideal dataset and the chemical and biological information on 
which these are based are given in Table 3. 
As assessment of inherent data quality has been dealt with in other reviews such assessments 
are not reported here, rather the reader is referred to key references in the area [40, 42-45]. 
The recommendations given below refer to assessment of dataset suitability for modelling in 
terms of coverage of chemical space, the presentation of the data and its accessibility to 
modellers.  
6.1 Recommendations to help modellers select the most appropriate dataset 
Based on the outcomes of the above assessment of the usefulness of the selected ADME 
datasets for modelling purposes, recommendations for selecting the most appropriate dataset 
are given below: 
1. The availability, size, format and types of chemical identifiers used should be considered, 
pragmatically during selection of the dataset for in silico modelling purposes.  
2. Excel remains a useful format for recording datasets for modelling, while CSV and text 
files are suitable alternatives. The pdf file format should only be used if data are not 
available in any other format; gif format requires manual re-entry of all data and is 
therefore least useful and not recommended for publishing datasets. 
3. Datasets with concordant multiple chemical identifiers, with at least one encoding the 
chemical structure in a machine-readable format (e.g. SMILES string), are preferred. 
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Datasets with only chemical names are potentially the most error-prone; names may be 
ambiguous or misspelt. The use of such datasets should be avoided wherever possible. 
4. Any conversion of a dataset (e.g. from pdf to Excel, or CAS number to SMILES strings) 
requires subsequent manual inspection to confirm that the data have been transferred / 
transformed correctly. Special attention needs to be paid to specific characters, symbols, 
missing data etc. 
Finally, it would be very useful to encourage data providers to report / publish their datasets 
in modelling-ready format adhering to the principles outlined above. The “benchmark” 
datasets provided here (supplementary information) can serve as examples. Having datasets 
in such a format will help modellers reduce not only time and effort in developing in silico 
models, but also will help to reduce transcription errors, which may be made during 
subsequent data archiving processes. The investigation by Young et al. showed that data 
translation errors range from 0.1 to 3.4% depending on the database in question [26]. 
Additionally, Fourches et al. showed that these transcription errors can complicate the 
generation of QSAR models [22]. Therefore, it is highly recommended to develop and apply 
standard guidance how to report datasets, especially in public resources. Creation of a 
centralised repository for the datasets in standardised formats, or expansion and greater use of 
existing repositories, such as QsarDB [102], which stores (Q)SAR / QSPR models, would be 
highly beneficial to modellers enhancing consistency of approaches and preventing 
duplication of effort. 
Knowledge of ADME properties is crucial in the safety assessment of chemicals. Read-across 
is currently one of the most commonly used alternative approaches for filling data gaps. The 
read-across assessment framework (RAAF) [103] makes specific reference to the importance 
of considering the influence of toxicokinetic properties. Hence, having easily accessible 
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ADME datasets (ideally stored in a centralised repository) would help to elucidate the 
influence of kinetics and exposure that underlie toxicity. Recently published Integrated 
Testing Strategies (ITS) and Intelligent Approaches to Testing and Assessment (IATA) have 
similarly emphasised the importance of ADME information when predicting in vivo effects 
[104]. ADME properties play an essential role in modulating the activity of xenobiotics in 
vivo, governing the temporal concentration at organs of interest which in turn determines the 
activity / toxicity profile of the compound. As the significance of ADME in determining 
activity is now widely acknowledged, reliable datasets of these properties, from which robust 
predictive models can be built, have never been more vital.  
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Figure 1. Factors affecting dataset modelability and the associated chemical and biological 
information  
*NB data quality assessment is not explicitly reviewed here, the reader is referred to the 
extensive reviews available elsewhere [40, 42-45]. 
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Table 1. A summary of the ADME properties considered in this investigation. 
ADME property Definition Property group 
ABSORPTION 
% Abs Percentage of available compound absorbed 
across (intestinal) barrier 
 
Absorption 
% HIA Percentage that is absorbed across the human 
gastrointestinal tract  
In Vitro (Oral) Absorption Data 
Caco2 Artificial membrane for predicting absorption - 
includes paracellular route and active uptake 
/efflux 
 
PAMPA Parallel artificial membrane permeability assay 
for predicting absorption - models passive 
diffusion only 
 
MDCK Madin-Darby canine kidney epithelial cells 
used to model absorption 
 
Skin Absorption  
Kp Skin permeability coefficient  
Jmax Maximum rate of flux across / into skin  
Uptake across respiratory tract 
Amount absorbed e.g. Weight of compound absorbed / kg body 
weight 
 
DISTRIBUTION 
%PPB Percentage of compound bound to plasma 
proteins 
 
 
%PPB, fb and fu in 
plasma 
fb Fraction bound to plasma proteins 
fu Fraction unbound in plasma (i.e. free fraction) 
fbt Fraction bound in tissues  
fbt, fut in tissues  
fut Fraction unbound in tissues 
Vd 
Vdu 
Apparent volume of distribution (Vd) = a 
hypothetical volume into which a compound 
distributes; Vdu = the volume for the unbound 
fraction 
 
 
Volume of distribution 
Ktb Tissue: blood partition coefficient  
BBB partitioning Blood brain barrier partitioning, ratio of 
concentrations between brain and blood (serum 
/ plasma)  
 
m:p The ratio of concentration between breast milk 
and plasma 
 
Blood:testes  The ratio of concentrations between blood and 
testes 
 
CI Clearance index for placental transfer of 
compounds usually expressed as a ratio using 
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antipyrine as a marker CI and TI for placenta 
transfer TI Transfer index for placental transfer of 
compounds  
In Vitro Blood-Brain Barrier (BBB) Partitioning 
PAMPA-BBB PAMPA Assay for BBB Partitioning  
In vitro BBB 
  
BBMEC Bovine Brain Microvessel Endothelial Cells 
METABOLISM 
Predominant 
enzyme 
responsible 
Identification of key enzymes (e.g. CYPP450 
3A4, 2C9, 2D6 etc.) 
 
 
 
 
Metabolism and % 
excreted unchanged 
% metabolised Total percentage metabolised  
% excreted The percentage of compound excreted 
unchanged in urine. 
Cl / Clh Cl = volume of blood from which compound is 
removed in a given time; Clh = Clearance by 
hepatic route (i.e. metabolism) 
Cyp Inhibition  Inhibition of Cytochrome P450 enzymes  
 In Vitro Metabolism Data 
Km Binding affinities for metabolic enzymes  
In vitro metabolism Vmax Maximum velocity of metabolic reaction 
Cliv Clearance rate in liver (obtained e.g. using liver 
slices, microsomes, S9 fraction or liver 
homogenate) 
ELIMINATION 
Clr Clearance by renal route (i.e. urinary excretion)  
Clearance  Cltot Sum clearance by all routes 
Composite Parameters 
F Bioavailability; fraction of dose that enters the 
systemic circulation  
 
AUC Area under concentration time curve 
Kinetic data Cmax Maximum concentration in blood / plasma 
Tmax Time to reach max concentration 
t½  Half–life i.e. the time taken for the 
concentration of a compound in the body to fall 
by half 
 
Transporter interactions  
Km  Substrate binding affinities (PgP, OATP etc.)  
Transporters Ki Inhibitors (PgP, OATP etc.) 
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Table 2. The summary of assessment of selected ADME datasets. 
ID ADME Endpoints 
Availability 
(Reference)  
Size  
(no. chemicals) 
 
Format Chemical identifiers 
BM 1 Absorption [83] 932 Excel Name, CAS, SMILES 
BM 2 Caco-2 [72] 1301 Excel Name, SMILES 
BM 3 PAMPA [84] 290 Pdf Name 
BM 4 MDCK [83] 246 Excel Name, CAS, SMILES 
BM 5 Kp [85] 283 Excel Name 
BM 6 Jmax [77]  278 Gif Name 
BM 7 %PPB, fb, fu in plasma [86] 1008 (808 +200) Excel + Pdf Name 
BM 8 %PPB, fb, fu in plasma [87] 554 Excel Name, CAS 
BM 9 Vd [87] 670 Excel Name, CAS 
BM 10 Ktb [88] 143 in vitro +196 
in vivo 
Pdf Name 
BM 11 BBB partitioning [71] 2053 Text Name, SMILES 
BM 12 m:p [75] 375 Word Name 
BM 13 Blood:testis  [67] 10 Word Name 
BM 14 Blood:testis [68] 7 Pdf Name 
BM 15 Blood:testis [69] 6 Pdf Name 
BM 16 CI and TI for placenta 
transfer 
[78] 78 CI + 56 TI Pdf Name, CAS 
BM 17 In Vitro BBB  [89] 16 Pdf Name 
BM 18 Metabolism and % 
excretion  
[90] 241 (excretion) Pdf Name 
BM 19 Metabolism and % 
excretion 
[91] 147 (CYP 
metabolism) 
Pdf Name, SMILES 
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BM 20 CYP inhibition [92] 702 (3A4) + 702 
(2D6) + 702 (2C9) 
Excel 
 
Name 
BM 21 CYP inhibition [93] 87 (1A2) Pdf Name 
BM 22 In vitro metabolism [94] 94 Pdf Name 
BM 23 Clearance by all routes [87] 670 Excel Name, CAS 
BM 24 Clearance by all routes [95] 503 Excel Name, SMILES 
BM 25 Bioavailability F [73] 1014 Sdf Name, SMILES 
BM 26 Bioavailability F [96] 995 Excel Name, SMILES 
BM 27 t ½  [87] 670 Excel Name, CAS 
BM 28 Transporter interactions [70] 3763 Excel Name, SMILES, CAS 
BM 29 Transporter interactions [74] 1302 Sdf Name, SMILES 
BM 30 Transporter interactions [97] 1275 Excel Name, SMILES 
BM 31 Transporter interactions [98] 225 Excel Name, SMILES 
BM - Benchmark 
PAMPA - Parallel artificial membrane permeability 
MDCK - Madin-Darby canine kidney  
Kp - Skin permeability coefficient 
Jmax - Maximum rate of flux 
PPB - Plasma protein binding 
fb - Fraction bound 
fu - Fraction unbound 
Vd - Volume of distribution 
Ktb - Tissue: blood partition coefficient 
BBB - Blood brain barrier 
m:p – milk:plasma 
CI - Clearance index 
TI - Transfer index 
CYP - Cytochromes P450 
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t ½ - Half–life 
CAS - Chemical Abstracts Service 
SMILES - Simplified Molecular Input Line Entry System
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Table 3. Characteristics of ideal datasets and their constitutive chemical and biological 
information 
Dataset Chemical Information Biological Information 
Freely, publicly-available 
 
Large number of compounds 
covering diverse chemical 
space 
 
Flexible format: information 
readily downloadable;  
allows for data manipulation 
\ transformation; 
interchangeable with other 
formats; user-friendly 
interface 
 
Standard identifiers used; 
consistency between 
identifiers confirmed 
 
Availability of the reference 
to the original study 
 
Accurate: quality controlled 
/ quality assured data 
Structures appropriately 
characterised and “cleaned” 
as necessary to ensure 
suitability for modelling e.g. 
removal of metallics, salt 
forms, tautomers etc. 
 
Identifiers to include: 
Nomenclature 
SMILES string 
InChIKey 
CAS number 
 
Pictorial representation (in a 
chemical standard format) 
Endpoint values stated with 
consistent units; statistical 
validity of measured values 
confirmed 
 
Adequate experimental 
detail reported 
 
Generic and endpoint-
specific sources of 
experimental variability 
identified and minimised: 
e. g. species, sex, strain, 
number of animals used, 
dosing regimen. 
 
Vehicle reported (same 
vehicle used where possible) 
 
 
SMILES – Simplified Molecular Input Line Entry System 
InChIKey - International Chemical Identifier Key 
CAS - Chemical Abstracts Service 
 
